AC Immune Announces Safety And Immunogenicity Results Through Week 100 In Part 1 Of VacSYn, Its Phase 2 Trial Of ACI-7104 In Patients With Early-Stage Parkinson’s Disease: All Primary Endpoints Were Met, Generally Safe And Well Tolerated; Strong Immunogenicity Demonstrated, With 100% Response Rate After Three Immunizations